Preclinical Anti-Treg Technology Platform for Cancer Vaccines

Breaking immune tolerance through the dual attack of "tumor + microenvironment." Creative Biolabs provides a state-of-the-art preclinical development platform targeting Regulatory T cells (Tregs) to maximize vaccine-induced antitumor immunity.

Our platform features the innovative T-win peptide technology and targeted depletion systems, which neutralize the "brakes" of the immune system and transform the TME into a gateway for therapeutic success.

Request Preclinical Project Design

Why Target Tregs? The Shift Toward Microenvironment-Aware Vaccines

Traditional cancer vaccines often fail because they ignore the immunosuppressive shield provided by Regulatory T cells (Tregs). Our Anti-Treg platform is designed based on the latest scientific shifts documented in recent literature:

▶ The "Dual Attack" Strategy: Shifting from "tumor-only" targeting to a synergistic approach that kills malignant cells while simultaneously depleting suppressive cells in the TME.
▶ Overcoming Immune Coldness: By targeting molecules like CCR4, IDO, or PD-L1 co-expressed in the TME, our vaccines "warm up" cold tumors for enhanced responsiveness.
▶ Precision Patient Selection: Leveraging baseline immunological profiles to identify populations most likely to benefit from Treg-targeted interventions.

Specialized Preclinical Anti-Treg Solutions

We provide a fully integrated suite of services to engineer vaccines that actively modulate the suppressive TME:

Targeted Depletion Strategies

Developing antibodies or peptide constructs (e.g., anti-CCR4 KW-0761 logic) that selectively deplete FOXP3+ Tregs to relieve tumor-associated immunosuppression.

Treg Depletion Validation

Quantitative in vitro and in vivo assessment of the vaccine's ability to selectively deplete FOXP3+ Tregs while sparing effector memory T-cell populations.

Biomarker Discovery

Identifying predictive markers like Absolute Lymphocyte Count (ALC) to correlate baseline immune status with post-treatment clinical outcomes.

Preclinical Synergy Modeling

Evaluating the combination of Anti-Treg vaccines with ICIs or small-molecule metabolic inhibitors in syngeneic and humanized mouse models.

Featured Preclinical Focus Areas

Targeting the most resilient immune escape mechanisms in solid tumor research:

CCR4-Based Depletion Design

Leveraging the KW-0761 mechanism to design systems that continuously monitor and deplete regulatory populations throughout the vaccine treatment cycle.

Explore CCR4 Logic →

Treg-to-Effector Reprogramming

Designing vaccines that exploit metabolic vulnerabilities to switch Tregs into IFN-γ-secreting "Th1-like" effector cells within the tumor.

Learn About Phenotype Switching →

ALC-Driven Stratification

Applying industry-validated lymphocyte analysis to screen for responders, ensuring preclinical studies reflect high-potential clinical cohorts.

View Predictive Modeling →

Adjuvant-Treg Interaction

Screening for specialized adjuvants (e.g., TLR7/8 agonists) that specifically block Treg induction while promoting robust DC-mediated cross-priming.

Get Adjuvant Details →

Agile Preclinical Anti-Treg Development Workflow

Our systematic pipeline ensures a seamless transition from molecular design to validated TME modulation:

Step 1: Multi-target Screening & Design

Activities: Identification of immune-modulating molecules (CCR4, IDO, PD-L1) co-expressed in your specific tumor model. Designing high-affinity constructs for targeted Treg neutralization.

Outcome: Verified lead constructs with optimal Treg-binding potential.

Step 2: Functional Depletion Validation

Activities: Quantifying the depletion kinetics of FOXP3+ cells in vitro and in preliminary in vivo dose-escalation studies to ensure sustained suppression relief.

Outcome: Functional proof-of-concept for T-cell mediated or antibody-mediated Anti-Treg activity.

Step 3: Formulation & Analytical Stability

Activities: Developing optimized formulations for vaccine-depletion combinations. Rigorous analytical characterization ensures high bioactivity and stability for animal studies.

Outcome: Standardized vaccine prototypes ready for preclinical dosing.

Step 4: In Vivo Efficacy & TME Mapping

Activities: Testing in syngeneic models to monitor tumor growth inhibition. We perform serial TME profiling to quantify the Treg/Effector T-cell ratio transition over time.

Outcome: Quantitative data on TME reversal and protective antitumor efficacy.

Step 5: Biomarker & Sensitivity Analysis

Activities: Analyzing lymphocyte subsets and other baseline markers to establish correlations with therapeutic response, mirroring clinical "Responders vs. Non-responders."

Outcome: A comprehensive preclinical package for IND-enabling decisions and clinical stratification logic.

Discuss Your Development Timeline

Proprietary Anti-Treg Technology Platforms

Our solutions are powered by industry-leading systems tailored for TME modulation:

Treg-Targeting Precision Engine: A sophisticated engineering platform that utilizes AI-driven structural modeling to design Anti-Treg vaccines and antibodies (e.g., targeting CCR4). It ensures a truly synergistic attack on the immune "brakes."

Validated for multiple immunosuppressive targets (CCR4, IDO, PD-L1)
Optimized for rapid screening of HLA-matched murine and human epitopes
High cargo purity verified by mass spectrometry

TME-Regulator Mapper: An advanced analytical suite combining multiplex immunofluorescence (mIF) and spatial transcriptomics. This platform allows us to visualize the spatial depletion of Tregs and the subsequent infiltration of effector T cells.

Simultaneous tracking of 7+ immune markers (CD8, FOXP3, Ki67, etc.)
Analysis of the "Immune Desert" vs. "Immune Infiltrated" zones
Correlation with local cytokine signatures post-depletion

Immuno-Switch Bio-assay: A specialized co-culture platform designed to monitor the reprogramming of suppressive cells. It identifies whether the vaccine-induced response is successfully flipping the TME from anti-inflammatory to pro-inflammatory.

Real-time metabolic tracking of suppressive cells
High-sensitivity Fluorospot for multi-cytokine detection
Ideal for assessing "Th1-like" Treg conversions

Treg-Targeting Engine

TME-Regulator Mapper

Immuno-Switch Assay

Scientific Insight: Precision Treg-Targeted Cancer Immunotherapy

Targeted Treg Depletion via Anti-CCR4 Antibody (Fujikawa et al., 2023)

Innovation: This integrated analysis of industry-led Phase 1a and 1b randomized controlled trials evaluates the efficacy of humanized anti-CCR4 antibody (KW-0761) in patients with advanced solid tumors. The study provides a blueprint for successful Treg-targeted therapeutic implementation.

Research Highlights:

Sustained Treg Depletion: The integrated data confirms that targeting CCR4 achieves potent and sustainable depletion of FOXP3+ CD4+ T cells across multiple solid tumor types.
Predictive Biomarkers: Significantly, higher baseline absolute lymphocyte counts (ALC) were found to correlate with improved clinical outcomes, enabling precision patient stratification for Treg-targeted therapies.
Clinical Practice Impact: This work supports the development of next-generation cancer vaccines by optimizing trial designs and screening for patient populations most likely to benefit from TME-regulatory interventions.

Blood laboratory parameter changes and their correlation with overall survival in KW-0761-treated patients.

Fig.1 Blood laboratory data changes and overall survival correlation under KW-0761 therapy.^1,2

Frequently Asked Questions

Q: How does the anti-CCR4 approach differ from standard vaccines?

A: While standard vaccines focus on antigens, the anti-CCR4 approach (like KW-0761) actively removes the suppressive FOXP3+ Treg barrier. This "clears the path" for the vaccine-induced effector cells to reach the tumor.

Q: Why are baseline lymphocyte levels important?

A: As shown in recent clinical analyses (Fujikawa et al., 2023), higher baseline lymphocytes often signal a more robust underlying immune system, which is critical for maximizing the therapeutic window once the Treg suppression is lifted.

Q: What animal models do you recommend for these studies?

A: We recommend syngeneic murine models with high Treg infiltration (like B16-F10) or humanized mouse models for evaluating HLA-matched human peptide/antibody candidates.

Related Resources

References:
1. Fujikawa, Kaoru, et al. "Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors." PloS one 18.9 (2023): e0291772.
2. Distributed under Open Access License CC BY 4.0, without modification.